We’re proud of our culture and the talented, bright and passionate people we employ. We nurture and celebrate individuals and what they bring to our team.
Below are just a few of our leaders.
Jonas is the CEO and co-founder of Deallus. Previously, Jonas was the Head and Director of Competitive Intelligence at Amgen Inc., and prior to this role he worked for Therapy Area Pain Control within AstraZeneca R&D. Before joining the life science sector, Jonas was an Assistant Professor and acting Deputy Director at the Department of Musculoskeletal Research at The National Institute for Working Life in Sweden.
Over his career, Jonas has facilitated over 120 strategic workshops such as war games and scenario analysis events and is experienced in all facets of the strategy consulting mix. He has provided advice to many of the world’s leading biopharmaceutical organisations across a range of sectors and is a recognised speaker at business schools as well as numerous pharmaceutical conventions and forums, most recently serving as the key note speaker during the esteemed PharmaCI (U.S) conference. In addition to his role as CEO at Deallus, Jonas is on the Board of Directors of Isofol Medical AB.
Julie Munch Khan is a Partner and vital account leader at Deallus. She has been with Deallus for over 7 years and has provided strategic marketing support for several leading brands on both a global and regional level, with expertise spanning clinical and commercial development strategies. Julie brings extensive brand plan development and life cycle management expertise, as well as personalised healthcare approaches across numerous disease areas to the team.
Julie started her consultancy career developing public healthcare policies in the UK. Prior to joining Deallus, Julie was a Senior Scientific Advisor in the healthcare division at Edelman where she was instrumental in supporting both pre-and post-launch marketing strategies as well as developing market access strategies for large pharma in the UK.
Brendan has been with Deallus for over 4 years and has extensive experience in providing strategic business insights to support key marketing and investment decisions. He has supported brands from early pre-launch through to patent expiration, and has worked across a wide range of therapy areas including HIV, anti-fungals, pain and diabetes. Brendan has experience with managing market analysis, forecasting, and primary market research projects supporting brands at all stages of the product lifecycle.
Prior to joining Deallus in the London office, Brendan worked for 12 years in the business insights groups for several major pharmaceutical and biotech companies, most recently completing an assignment in the global analytics group for AstraZeneca working on the in-line and early emerging assets in the anti-infective franchise. He has also supported major market launches for Lundbeck and Amgen, working in the fields of mental health and osteoporosis and helping to develop brand strategies for the UK market.
Neal has been a part of Deallus for over 2 years and has over 8 years of experience as a consultant for medical device and pharmaceutical companies. Neal has managed projects across various geographies, with a large amount taking place in Japan and central Europe. He has expertise in a number of different therapy areas including immune-oncology and orphan diseases, and his experience with pricing and reimbursement as well as product and portfolio planning are an asset to the team.
Prior to joining Deallus, Neal spent 5 years working at the LEK Tokyo office, focusing exclusively on Japan market assessments, market entry strategy and pricing. More recently, Neal worked in London on pricing and market access assessments, delivering recommendations for EU launches. He is also currently in the process of furthering his education by earning a postgraduate certificate in Health Economics.
Eugénie has been with Deallus for over 6 years and has an impressive background in both neuroendocrinology and auto-immune disorders. During her time at Deallus, Eugénie has led numerous projects centered on competitive readiness, with a focus on delivering critical and bespoke insights to key Industry clients. In particular, many of Eugenie’s projects have supported top in-market brands within chronic and auto-immune diseases, as well as vaccines and pipeline areas with critical unmet needs.
Eugénie’s strong analytical, management and facilitation skills have enabled her to lead clients, projects and teams across the breadth of our services. She has designed, led, and facilitated an extensive number of competitive simulation workshops and competitive readiness training courses since being a part of Deallus.
New to Deallus, Mike brings extensive experience in the oncology space to the team. He has strong expertise with managing brands in rare disease, HIV, and women’s health, and has spent the majority of his career leading marketing teams at major pharmaceutical companies including Pfizer and Ipsen Biopharmaceuticals. His experience includes developing market growth strategies as well as brand positioning, pricing, and patient strategy.
Mike’s experience provides a wealth of knowledge from the client and marketing side, as well as years of client relations experience throughout the life science industry. His background leaves him well equipped to contribute to vital business development initiatives and commercial processes.
Yuki Sato is the Representative Director of Deallus Tokyo, responsible for driving consulting services in the life sciences sector in Japan and the Asia Pacific Region. Yuki brings a strong pharmaceutical industry background background to Deallus as well as a talent for managing extensive global projects. Over the past 10 years, he has worked and developed expertise in such areas as branding, marketing, regulatory, R&D decision making, and medical affairs.
Prior to joining Deallus, Yuki served Ashfield Healthcare Communications as Director of Account & Business Development, and he was the key strategic contact for clients based in Japan. His previous positions also include President of the Tokyo Office at Brand Institute, where he provided the pharmaceutical industry with regulatory expertise and strategy in brand development.
Jesper is a Deallus consultant who has led a wide range of projects over his 5 year career at Deallus. He offers extensive experience in competitive landscape monitoring, manufacturing and diagnostics technology assessments, and global positioning and brand planning projects. His expertise covers several therapy areas including oncology, respiratory, rheumatology and rare diseases. Additionally, Jesper is leading internal and external training activities including engagements on Competitive Readiness best practices within the pharmaceutical industry.
Prior to joining Deallus, Jesper served as COO, head of strategy and BD, and member of the board of directors in a technology start-up in Cambridge, UK. He has extensive experience in the process of building a strong evidence base from which to derive the key implications and actionable recommendations necessary to any strategic decision-making process.
Hormoz has been a part of Deallus for over 5 years. He is a strong project lead with expertise as a trusted thought partner and industry consultant within oncology, immunology, cardiovascular, respiratory, metabolic, neuroscience, and orphan/rare disease areas. During his time with Deallus, Hormoz has successfully facilitated strategic and tactical engagements involving new product planning, clinical development, product launch, market landscaping, competitive benchmarking, patient support, digital technology integration, and market access.
Hormoz has also supported a breadth of project scopes, including global initiatives focused on life cycle management, commercial opportunity assessment, generic entry scenario planning, biologic manufacturing, KOL/payer perspectives, companion diagnostics, and biosimilars. His in-depth knowledge base is an asset to the Deallus team.